BAX - Baxter International Inc.
| Previous Close | 69.46 |
| Open | 69.46 |
| Bid | 69.37 x 1300 |
| Ask | 69.35 x 1400 |
| Day's Range | 69.15 - 69.73 |
| 52 Week Range | 62.52 - 78.38 |
| Volume | 164,319 |
| Avg. Volume | 2,940,739 |
| Market Cap | 36.944B |
| Beta (3Y Monthly) | 0.89 |
| PE Ratio (TTM) | 42.11 |
| EPS (TTM) | 1.64 |
| Earnings Date | Oct 31, 2018 |
| Forward Dividend & Yield | 0.76 (1.09%) |
| Ex-Dividend Date | 2018-08-30 |
| 1y Target Est | 80.29 |
- Zacks•1 hour ago
Medidata (MDSO) Tops Earnings & Revenue Estimates in Q3
Strong performance in the Subscription revenues segment drives Medidata???s (MDSO) results in Q3. Professional services also posted steady growth.
Markit•2 days agoSee what the IHS Markit Score report has to say about Baxter International Inc.
Baxter International Inc NYSE:BAX
Market Realist•3 days agoWhat Analysts Recommend for Stryker Stock
Of the total 28 analysts covering Stryker (SYK) in October 2018, 19 analysts have given the stock a “buy” or higher rating, and nine analysts have given Stryker a “hold” rating. The mean rating for Stryker is 1.93 with a target price of $187.27, which implies an upside potential of 8.2% over Stryker’s closing price of $173.1 on October 18. In comparison, peers Baxter International (BAX), Boston Scientific (BSX), and Zimmer Biomet Holdings (ZBH) have a mean rating of 2.41x, 1.52x, and 2.31x, respectively, and a target price of $79.79, $41.57, and $136.92, respectively.
- Zacks•3 days ago
Has Baxter International (BAX) Outpaced Other Medical Stocks This Year?
Is (BAX) Outperforming Other Medical Stocks This Year?
- Zacks•3 days ago
BAX vs. BSX: Which Stock Should Value Investors Buy Now?
BAX vs. BSX: Which Stock Is the Better Value Option?
- Zacks•3 days ago
Mallinckrodt (MNK) Gets $26 Million as Funding From BARDA
Mallinckrodt (MNK) gets $26 million for additional funding from BARDA for pediatric studies of StrataGraft skin tissue in thermal burns.
Market Realist•3 days agoA Look at Operational Performance Expectations for Stryker in Q3
Stryker’s (SYK) gross income is expected to increase by 8.63% from $1.98 billion in the third quarter of 2017 to $2.16 billion in the third quarter of 2018. Stryker’s gross margin is expected to expand from 66.03% for the third quarter of fiscal 2017 to 66.18% for the third quarter of fiscal 2018. Stryker’s gross margins for fiscal 2018 and 2019 are expected at 66.27% and 66.48%, respectively.
- Business Wire•3 days ago
Baxter to Showcase Critical Care Innovation at the 2018 European Society of Intensive Care Medicine Congress
Baxter International Inc. (BAX), a leading global medical products company, will highlight its latest innovations in critical care at the 2018 European Society of Intensive Care Medicine (ESICM) congress in Paris from Oct. 20-24. The company will also sponsor two symposia to address top issues facing critical care clinicians: reducing IV infusion medication programming errors and innovation in continuous renal replacement therapy (CRRT) and extracorporeal removal of inflammatory mediators in sepsis management.
Market Realist•4 days agoWhat Analysts Expect for Boston Scientific Stock
Of the total 25 analysts covering Boston Scientific (BSX) in October 2018, 22 analysts have given Boston Scientific a “buy” or higher rating, and three analysts have given Boston Scientific a “hold” rating. The mean rating for Boston Scientific is 1.52 with a target price of $41.57, which implies an upside potential of 9.4% over Boston Scientific’s closing price of $38.0 on October 17, 2018.
Market Realist•4 days agoWhat Will BSX’s Q3 Operational Performance Look Like?
Boston Scientific’s (BSX) gross income is expected to increase by 9.26% from $1.58 billion in the third quarter of fiscal 2017 to $1.73 billion in the third quarter of fiscal 2018. Its gross margin is expected to expand from 71.33% for the third quarter of fiscal 2017 to 71.95% for the third quarter of fiscal 2018.
Markit•4 days agoSee what the IHS Markit Score report has to say about Baxter International Inc.
Baxter International Inc NYSE:BAX
GuruFocus.com•5 days agoBarclays Takes Action on Health Care Stocks
The firm has initiated coverage of Abbott Labs, Boston Scientific, Medtronic, Stryker and others
- Zacks•6 days ago
What's in Store for Cerner (CERN) This Earnings Season?
Cerner's (CERN) third-quarter 2018 results are likely to be hurt by soft segmental results; guidance promising.
- Zacks•10 days ago
Cerner's Millennium Platform Integrated at McLaren Hospital
Cerner's (CERN) Millennium HCIT platform sees a series of developments in 2018.
- Zacks•10 days ago
Can Baxter (BAX) Keep the Earnings Surprise Streak Alive?
Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks•11 days ago
Baxter & ASPEN Launch PN Tools to Boost Clinical Nutrition
Baxter (BAX) and ASPEN's SmartPN lends the company a competitive edge in the MedTech space.
- GlobeNewswire•11 days ago
Investor Expectations to Drive Momentum within Materion, Iridium Communications, Natural Health Trends, Revance Therapeutics, Baxter International, and Alexion Pharmaceuticals — Discovering Underlying Factors of Influence
NEW YORK, Oct. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•12 days ago
Baxter and ASPEN Launch “SmartPN” Tools to Reinforce Appropriate Use of Parenteral Nutrition
Today the American Society for Parenteral and Enteral Nutrition (ASPEN), an organization which drives the science and practice of clinical nutrition, and Baxter International Inc. (BAX), a global leader in clinical nutrition, launched an educational video series on the appropriate use of parenteral nutrition (PN), as part of the organizations’ “SmartPN” collaboration to help reduce clinical malnutrition that was announced last year.
- Insider Monkey•15 days ago
Suvretta Capital Management’s Return, AUM, and Holdings
Suvretta Capital Management is a young New York-based hedge fund founded by its current portfolio manager, Aaron Cowen, in 2012. Prior to founding Suvretta, Mr. Cowen honed his investment acumen working at two acclaimed large hedge funds: as a portfolio manager at Soros Fund Management, and as a CIO at SAC Capital. Prior to those positions, […]
Market Realist•17 days agoABT Stock Registered a 52-Week High in October
On October 4, Abbott Laboratories (ABT) ended the trading day at $71.82, down ~0.31% from the previous day’s close. The stock registered a 52-week high of $74.15 on October 1. Throughout the week, it’s fallen ~1.6%.
- Zacks•17 days ago
Zacks.com highlights: Lululemon Athletica, Malibu Boats, Surmodics and Baxter International
Zacks.com highlights: Lululemon Athletica, Malibu Boats, Surmodics and Baxter International
Market Realist•17 days agoAnalysts’ Recommendations on ABT Stock in October
Abbott Laboratories (ABT) offers market-leading products and solutions across its Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals operating segments.
- Business Wire•18 days ago
Baxter to Present at the 27th Annual Credit Suisse Healthcare Conference
Baxter International Inc. , a leading global medical products company, will present at the 27th Annual Credit Suisse Healthcare Conference in Scottsdale, Ariz. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present on Wednesday, November 14, 2018 at 8:00 a.m.
- Zacks•18 days ago
Buy These 4 Efficient Stocks for Stellar Returns
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
